Analyst upgrades: Celera Genomics, Plantronics, Nymex
Posted Dec 19th 2007 12:02PM by Eric Buscemi
Filed under: Analyst Upgrades and Downgrades, Schlumberger Limited (SLB)
.gif)
MOST NOTEWORTHY: Celera Genomics, Plantronics and Nymex were today's noteworthy upgrades:
- JMP Securities upgraded Celera Group, Applera Corp. (NYSE: CRA) to Outperform from Market Perform, as they believe an announcement on the company's evaluation of its tracking stock could come as early as 1Q08, a split of Celera/Applied Biosystems could occur by FY08, and a new finding in a peer-review journal that predicts risk of coronary heart disease and statin benefit within the next six weeks.
- Baird raised Plantronics (NYSE: PLT) to Outperform from Neutral based on valuation, strength in the Center and Office segment, and negative sentiment on Mobile revenues unwarranted.
- Deutsche Bank upgraded shares of NYMEX (NYSE: NMX) to Buy from Hold and raised their target to $160 from $145 to reflect stabilized floor volumes, increased trading of commodities and acquisition potential consensus estimates that are too low. Deutsche named NMX their top exchange idea for 2008.
OTHER UPGRADES:
Tags: AGO, CRA, NILE, NMX, PLT, SLB, UPGRADES
Walmart's New Health Food Push: Is It Too Hard to Swallow?
Bonds Are a 'Safe' Investment: A Big Lie Gets Even Bigger
Goldman Earnings Sink After Buffett Dividend
Johnson & Johnson's Income Falls 23%
Burberry Shares Leap on Sales Update
